NCT05030493 - An Additional Analysis of Data from the PARADIGM Exploratory Study (NCT02394834) in Patients with Advanced/Recurrent Colorectal Cancer | Biotech Hunter

Enrollment

787

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

Colorectal Cancer

Interventions

DRUG

mFOLFOX6 + panitumumab combination therapy

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion

DRUG

mFOLFOX6 + bevacizumab combination therapy

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion

Trial Locations (1)

Unknown

Takeda selected site, Tokyo